Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
NCT01669239
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
83
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Liposomal Doxorubicin
Sponsor
SOLTI Breast Cancer Research Group